CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy
Cystic fibrosis-related diabetes (CFRD) is a common complication of cystic fibrosis that is associated with worse outcomes and higher mortality rates. CF transmembrane conductance regulator gene (CFTR) modulators have shown favorable effects on lung function, pulmonary exacerbations, and nutrition s...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-12-01
|
| Series: | Journal of Clinical & Translational Endocrinology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214623722000151 |
| _version_ | 1828091933870784512 |
|---|---|
| author | Hanna Crow Charles Bengtson Xiaosong Shi Leland Graves, III Abeer Anabtawi |
| author_facet | Hanna Crow Charles Bengtson Xiaosong Shi Leland Graves, III Abeer Anabtawi |
| author_sort | Hanna Crow |
| collection | DOAJ |
| description | Cystic fibrosis-related diabetes (CFRD) is a common complication of cystic fibrosis that is associated with worse outcomes and higher mortality rates. CF transmembrane conductance regulator gene (CFTR) modulators have shown favorable effects on lung function, pulmonary exacerbations, and nutrition status. However, data regarding effects of CFTR modulators on glycemic control among those with CFRD is lacking. In this retrospective study, CGM data was analyzed to determine effect of elexacaftortezacaftor- ivacaftor therapy (ETI), a CFTR modulator, on glucose control among patients with CFRD. No difference was seen in glucose patterns after 3- and 6- months of starting ETI. |
| first_indexed | 2024-04-11T06:21:43Z |
| format | Article |
| id | doaj.art-49800a0080554cb7b2375825a90b3b07 |
| institution | Directory Open Access Journal |
| issn | 2214-6237 |
| language | English |
| last_indexed | 2024-04-11T06:21:43Z |
| publishDate | 2022-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Clinical & Translational Endocrinology |
| spelling | doaj.art-49800a0080554cb7b2375825a90b3b072022-12-22T04:40:33ZengElsevierJournal of Clinical & Translational Endocrinology2214-62372022-12-0130100307CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapyHanna Crow0Charles Bengtson1Xiaosong Shi2Leland Graves, III3Abeer Anabtawi4University of Kansas Medical Center, Department of Internal Medicine, Division of Endocrinology, Metabolism & Clinical Pharmacology, 4000 Cambridge Blvd, Kansas City, KS 66160, USAUniversity of Kansas Medical Center, Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, 4000 Cambridge Blvd, Kansas City, KS 66160, USAUniversity of Kansas Medical Center, Department of Biostatistics & Data Science, 4000 Cambridge Blvd, Kansas City, KS 66160, USAUniversity of Kansas Medical Center, Department of Internal Medicine, Division of Endocrinology, Metabolism & Clinical Pharmacology, 4000 Cambridge Blvd, Kansas City, KS 66160, USAUniversity of Kansas Medical Center, Department of Internal Medicine, Division of Endocrinology, Metabolism & Clinical Pharmacology, 4000 Cambridge Blvd, Kansas City, KS 66160, USA; Corresponding author.Cystic fibrosis-related diabetes (CFRD) is a common complication of cystic fibrosis that is associated with worse outcomes and higher mortality rates. CF transmembrane conductance regulator gene (CFTR) modulators have shown favorable effects on lung function, pulmonary exacerbations, and nutrition status. However, data regarding effects of CFTR modulators on glycemic control among those with CFRD is lacking. In this retrospective study, CGM data was analyzed to determine effect of elexacaftortezacaftor- ivacaftor therapy (ETI), a CFTR modulator, on glucose control among patients with CFRD. No difference was seen in glucose patterns after 3- and 6- months of starting ETI.http://www.sciencedirect.com/science/article/pii/S2214623722000151CGMCystic fibrosis-related diabetesCFTR modulatorElexacaftor-tezacaftorivacaftor (ETI) |
| spellingShingle | Hanna Crow Charles Bengtson Xiaosong Shi Leland Graves, III Abeer Anabtawi CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy Journal of Clinical & Translational Endocrinology CGM Cystic fibrosis-related diabetes CFTR modulator Elexacaftor-tezacaftorivacaftor (ETI) |
| title | CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy |
| title_full | CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy |
| title_fullStr | CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy |
| title_full_unstemmed | CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy |
| title_short | CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy |
| title_sort | cgm patterns in adults with cystic fibrosis related diabetes before and after elexacaftor tezacaftor ivacaftor therapy |
| topic | CGM Cystic fibrosis-related diabetes CFTR modulator Elexacaftor-tezacaftorivacaftor (ETI) |
| url | http://www.sciencedirect.com/science/article/pii/S2214623722000151 |
| work_keys_str_mv | AT hannacrow cgmpatternsinadultswithcysticfibrosisrelateddiabetesbeforeandafterelexacaftortezacaftorivacaftortherapy AT charlesbengtson cgmpatternsinadultswithcysticfibrosisrelateddiabetesbeforeandafterelexacaftortezacaftorivacaftortherapy AT xiaosongshi cgmpatternsinadultswithcysticfibrosisrelateddiabetesbeforeandafterelexacaftortezacaftorivacaftortherapy AT lelandgravesiii cgmpatternsinadultswithcysticfibrosisrelateddiabetesbeforeandafterelexacaftortezacaftorivacaftortherapy AT abeeranabtawi cgmpatternsinadultswithcysticfibrosisrelateddiabetesbeforeandafterelexacaftortezacaftorivacaftortherapy |